Mangalam Drugs & Organics Limited (MANGALAM.BO)
INR 80.89
(0.21%)
INR 80.89
(0.21%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 3.68 Billion INR | 0.72% |
| 2022 | 3.65 Billion INR | -18.2% |
| 2021 | 4.47 Billion INR | 17.79% |
| 2020 | 3.79 Billion INR | 34.58% |
| 2019 | 2.82 Billion INR | 26.02% |
| 2018 | 2.23 Billion INR | -19.78% |
| 2017 | 2.79 Billion INR | -8.27% |
| 2016 | 3.04 Billion INR | 3.15% |
| 2015 | 2.95 Billion INR | 33.75% |
| 2014 | 2.2 Billion INR | 80.04% |
| 2013 | 1.22 Billion INR | -2.19% |
| 2012 | 1.25 Billion INR | -18.23% |
| 2011 | 1.53 Billion INR | 20.25% |
| 2010 | 1.27 Billion INR | 13.44% |
| 2009 | 1.12 Billion INR | 9.66% |
| 2008 | 1.02 Billion INR | 7.79% |
| 2007 | 949.99 Million INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 765.36 Million INR | -25.14% |
| 2023 Q1 | 870.03 Million INR | -3.13% |
| 2023 FY | 3.68 Billion INR | 0.72% |
| 2023 Q4 | 1.02 Billion INR | 5.03% |
| 2023 Q3 | 973.35 Million INR | 19.63% |
| 2023 Q2 | 813.66 Million INR | -6.48% |
| 2022 Q3 | 620.87 Million INR | -41.63% |
| 2022 FY | 3.65 Billion INR | -18.2% |
| 2022 Q4 | 898.12 Million INR | 44.65% |
| 2022 Q1 | 1.09 Billion INR | -18.64% |
| 2022 Q2 | 1.06 Billion INR | -2.83% |
| 2021 Q2 | 1.14 Billion INR | 8.99% |
| 2021 Q4 | 1.34 Billion INR | 43.39% |
| 2021 Q1 | 1.04 Billion INR | 15.68% |
| 2021 Q3 | 938.36 Million INR | -17.83% |
| 2021 FY | 4.47 Billion INR | 17.79% |
| 2020 Q1 | 1.03 Billion INR | 17.84% |
| 2020 FY | 3.79 Billion INR | 34.58% |
| 2020 Q3 | 886.87 Million INR | -8.59% |
| 2020 Q4 | 905.74 Million INR | 2.13% |
| 2020 Q2 | 970.25 Million INR | -6.38% |
| 2019 FY | 2.82 Billion INR | 26.02% |
| 2019 Q1 | 650.42 Million INR | 46.3% |
| 2019 Q4 | 879.52 Million INR | 41.99% |
| 2019 Q2 | 672.73 Million INR | 3.43% |
| 2019 Q3 | 619.43 Million INR | -7.92% |
| 2018 FY | 2.23 Billion INR | -19.78% |
| 2018 Q4 | 444.57 Million INR | -8.49% |
| 2018 Q3 | 485.82 Million INR | -32.43% |
| 2018 Q2 | 719 Million INR | 21.85% |
| 2018 Q1 | 590.07 Million INR | -12.19% |
| 2017 Q3 | 739.07 Million INR | -11.11% |
| 2017 Q2 | 831.41 Million INR | 50.79% |
| 2017 FY | 2.79 Billion INR | -8.27% |
| 2017 Q1 | 551.35 Million INR | -33.5% |
| 2017 Q4 | 671.95 Million INR | -9.08% |
| 2016 Q2 | 761.04 Million INR | 13.64% |
| 2016 Q1 | 669.72 Million INR | -5.07% |
| 2016 Q4 | 829.09 Million INR | 2.97% |
| 2016 FY | 3.04 Billion INR | 3.15% |
| 2016 Q3 | 805.19 Million INR | 5.8% |
| 2015 Q1 | 695.6 Million INR | -13.47% |
| 2015 Q2 | 679.44 Million INR | -2.32% |
| 2015 FY | 2.95 Billion INR | 33.75% |
| 2015 Q4 | 705.5 Million INR | -14.33% |
| 2015 Q3 | 823.54 Million INR | 21.21% |
| 2014 Q2 | 408.49 Million INR | 5.94% |
| 2014 Q3 | 607.83 Million INR | 48.8% |
| 2014 FY | 2.2 Billion INR | 80.04% |
| 2014 Q4 | 803.93 Million INR | 32.26% |
| 2014 Q1 | 385.58 Million INR | 2.07% |
| 2013 Q1 | 183.54 Million INR | -60.02% |
| 2013 Q2 | 281.26 Million INR | 53.24% |
| 2013 FY | 1.22 Billion INR | -2.19% |
| 2013 Q4 | 377.74 Million INR | -0.76% |
| 2013 Q3 | 380.63 Million INR | 35.33% |
| 2012 Q1 | 237.59 Million INR | -42.8% |
| 2012 FY | 1.25 Billion INR | -18.23% |
| 2012 Q4 | 459.05 Million INR | 29.36% |
| 2012 Q3 | 354.87 Million INR | 76.5% |
| 2012 Q2 | 201.06 Million INR | -15.37% |
| 2011 FY | 1.53 Billion INR | 20.25% |
| 2011 Q4 | 415.37 Million INR | 9.99% |
| 2011 Q3 | 377.65 Million INR | 0.0% |
| 2010 FY | 1.27 Billion INR | 13.44% |
| 2009 FY | 1.12 Billion INR | 9.66% |
| 2008 FY | 1.02 Billion INR | 7.79% |
| 2007 FY | 949.99 Million INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bal Pharma Limited | 3.39 Billion INR | -8.66% |
| Achyut Healthcare Limited | 61.36 Million INR | -5906.205% |
| Alkem Laboratories Limited | 126.67 Billion INR | 97.09% |
| Divi's Laboratories Limited | 78.45 Billion INR | 95.302% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 96.88% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 83.856% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -631.027% |
| Mankind Pharma Limited | 103.34 Billion INR | 96.433% |
| Medicamen Biotech Limited | 1.79 Billion INR | -105.567% |
| Medico Remedies Limited | 1.44 Billion INR | -154.342% |
| Megasoft Limited | 373.95 Million INR | -885.671% |
| Procter & Gamble Health Limited | 11.51 Billion INR | 67.983% |
| Piramal Pharma Limited | 81.71 Billion INR | 95.489% |
| Sequent Scientific Limited | 13.69 Billion INR | 73.09% |
| Sigachi Industries Limited | 3.98 Billion INR | 7.61% |
| Ajanta Pharma Limited | 42.08 Billion INR | 91.242% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 99.24% |
| Brooks Laboratories Limited | 794.86 Million INR | -363.722% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 79.697% |
| Themis Medicare Limited | 3.81 Billion INR | 3.449% |
| Unichem Laboratories Limited | 16.57 Billion INR | 77.761% |
| Hester Biosciences Limited | 3.04 Billion INR | -21.031% |
| Venus Remedies Limited | 5.91 Billion INR | 37.679% |
| Indoco Remedies Limited | 17.89 Billion INR | 79.402% |
| Ind-Swift Limited | 5.02 Billion INR | 26.643% |
| Aarti Drugs Limited | 25.28 Billion INR | 85.423% |
| Alpa Laboratories Limited | 1.08 Billion INR | -238.972% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 71.549% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 98.68% |
| Granules India Limited | 45.06 Billion INR | 91.821% |
| Gufic Biosciences Limited | 8.06 Billion INR | 54.306% |
| Hikal Limited | 17.84 Billion INR | 79.346% |
| RPG Life Sciences Limited | 5.82 Billion INR | 36.673% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | 64.941% |
| Windlas Biotech Limited | 6.3 Billion INR | 41.582% |
| ZIM Laboratories Limited | 3.67 Billion INR | -0.319% |
| Ind-Swift Laboratories Limited | 12.8 Billion INR | 71.224% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 82.605% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 94.501% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 98.716% |
| Bajaj HealthCare Limited | 4.73 Billion INR | 22.142% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -820.675% |
| Ipca Laboratories Limited | 76.22 Billion INR | 95.164% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -253.28% |
| Laurus Labs Limited | 50.01 Billion INR | 92.631% |
| NATCO Pharma Limited | 40.02 Billion INR | 90.79% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 78.113% |
| Shilpa Medicare Limited | 11.51 Billion INR | 67.993% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | 70.236% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 96.524% |
| Wanbury Limited | 5.75 Billion INR | 35.969% |
| Wockhardt Limited | 27.89 Billion INR | 86.784% |
| Strides Pharma Science Limited | 40.51 Billion INR | 90.901% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | 52.146% |
| Suven Life Sciences Limited | 116.92 Million INR | -3052.296% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | 12.496% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 93.969% |
| Eris Lifesciences Limited | 20.09 Billion INR | 81.654% |
| Lupin Limited | 200.1 Billion INR | 98.158% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -387.912% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -42.181% |
| Valiant Laboratories Limited | 1.82 Billion INR | -102.461% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 98.062% |
| FDC Limited | 19.42 Billion INR | 81.029% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 89.421% |
| Novartis India Limited | 3.35 Billion INR | -10.005% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -76.613% |
| Neuland Laboratories Limited | 15.58 Billion INR | 76.351% |
| Morepen Laboratories Limited | 17.01 Billion INR | 78.342% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -138.77% |